directory_dummy_post() PubMedLinks EACPT PubMedLinks – EACPT


Membership data is stored with Multiregistration. Click here to retrieve your password.


Comments are closed. You can not add new comments.

  1. Respectable board and honorouable managers,
    Would u kindly send me an official invitationto help me accomplish my pspers an propose officially to my university to finish my papers earlier and b able to b off work during this period..,,,.
    Shall b any discount from the eacpt, as long as i am a member
    Lots of thanks and appreciation

  2. Can i still attend the switzerland conference?
    If possible would u help me in registeration and send me an invitation for speaker?

  3. In accordance to EACPT statement I would like to emphasise that the possible risk is connected not only with ACE inhibitors, but also with angiotensin II receptor blockers (ARBs). Further, “the European Society of Cardiology (ESC) has issued a statement urging physicians and patients to continue treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), in light of a newly described theory that those agents could increase the risk of developing COVID-19 and/or worsen its severity. The concern arises from the observation that the new coronavirus SARS-CoV-2 causing COVID-19 binds to angiotensin-converting enzyme 2 (ACE2) to infect cells, and both ACE inhibitors and ARBs increase ACE2 levels.”

    All the best from Croatia,

    Dinko Vitezic


Updated on 2016-05-02T07:46:05+00:00, by Dennis Reinitz.

Skip to toolbar